MONEY

AngioDynamics retains Buy stock rating from Wainwright on RECOVER-AV trial

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 21, 2024 - 00:00
AngioDynamics retains Buy stock rating from Wainwright on RECOVER-AV trial
Read More

Tags:

Previous Article

Komatsu stock downgraded to underperform, price target cut on profit forecast

Next Article

RENN Fund CEO Murray Stahl buys $2,704 worth of company stock

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Mizuho maintains Outperform rating on Gilead stock with no price target change

Mizuho maintains Outperform rating on Gilead stock with...

Tomas Kauer - Mode... Sep 13, 2024

Goldman Sachs reiterates Buy on 4D Molecular Therapeutics, highlights promising gene therapy results

Goldman Sachs reiterates Buy on 4D Molecular Therapeuti...

Tomas Kauer - Mode... Sep 19, 2024

Sopra Steria Group: Disclosure of the Total Number of Shares and Voting Rights as at 31 August 2024

Sopra Steria Group: Disclosure of the Total Number of S...

Tomas Kauer - Mode... Sep 18, 2024